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Question
Are levo acetyl methadol (LAAM) and buprenorphine as
effective as methadone for substitution treatment of opioid
dependence?
Trial details
Design: Randomised controlled trial, double-blind.
Setting: Outpatient clinic in Baltimore, United States.
Participants: 220 people categorised as opioid dependent by 
DSM-IV;1 groups similar on demographics and drug use history. 
Exclusion criteria were medical and psychiatric illness requiring 
long-term medication, and pregnancy.
Interventions: (i) Levo acetyl methadol (LAAM) at 75–115 mg, (ii) 
buprenorphine at 16–32 mg, (iii) methadone at 60–100 mg (“high 
dose”), or (iv) methadone at 20 mg (“low dose”). LAAM and 
buprenorphine were given three times a week, methadone daily. 
LAAM and methadone were given orally, buprenorphine sublin-
gually. Participants attended the clinic daily for two weeks of dose 
induction, then thrice weekly with take-home doses. The scheduled 
duration of the trial was 17 weeks.
Main outcome measures: Retention in treatment; illicit drug use; 
participants’ global ratings of their drug problem.
Main results: Days retained in the study (mean  SE) — LAAM (i), 
89  6; buprenorphine (ii), 96  4; “high dose” methadone (iii), 
105  4; “low dose” methadone (iv) 70  4. Significantly more days 
retained for groups (i), (ii) and (iii) compared with group (iv) 
(P < 0.001), and group (iii) compared with group (i) (P = 0.02). Trial 
was completed by 53% of group (i), 58% of group (ii), 73% of group 
(iii), and 20% of group (iv), with 4, 3, 6 and 26 of groups (i), (ii), (iii) 
and (iv), respectively, transferred to rescue treatment (standard 
methadone maintenance). Twelve or more consecutive opioid-
negative urine specimens were obtained in 36% of group (i), 26% of 
group (ii), 28% of group (iii) and 8% of group (iv) (P < 0.005).
Conclusion: Compared with low-dose methadone, LAAM, 
buprenorphine and high-dose methadone substantially reduce the 
use of illicit opioids.
Commentary
Rationale for the trial
Substitution treatment with methadone has proven effective
in reducing heroin use and providing an opportunity for
improvement in health and social functioning for dependent
drug users.2 However, methadone maintenance does not
suit all people. LAAM, a full opioid agonist, and buprenor-
phine, a partial agonist, are promising alternatives to metha-
done maintenance. Buprenorphine has a lower risk of
overdose than methadone, and both buprenorphine and
LAAM can be given less frequently than daily, providing
increased flexibility and reduced costs. Previous research
supports the feasibility of substitution treatment with
LAAM and buprenorphine, and each of these drugs has
been compared with methadone in controlled studies.2 The
rationale for this trial by Johnson and colleagues was to
compare LAAM and buprenorphine with standard (“high
dose”) methadone maintenance and a control in a single
study. Methadone at 20 mg daily was chosen as the control
because it has the capacity to suppress opioid withdrawal,
but is only minimally effective as a maintenance treatment.
For ethical reasons, a rescue treatment was available for all
study participants who responded poorly to experimental
treatment.
Trial methods
Participants were stratified, then allocated by random
number generation, with participants and clinic staff una-
ware of group assignments and doses. Each day participants
received three solutions (two oral, one sublingual), only one
of which contained active medication. Otherwise all groups
received equivalent treatment. It seems likely that partici-
pants in the “low dose” methadone group might have been
able to guess their group allocation, but the adequacy of
blinding was not discussed by the authors. There were clear
definitions for transfer to rescue treatment, drop-out, and
calculation of retention in treatment, and adjustments for
missing data. All analyses were based on intention to treat.
New information
LAAM and buprenorphine are significantly more effective
than “low dose” methadone in reducing illicit opioid use,
and of similar effectiveness to “high dose” methadone. Illicit
opioid use was somewhat lower for the LAAM group — the
use of larger group sizes might have provided sufficient
statistical power for a significant difference to be detected.
Participants in the “high dose” methadone group were
retained in treatment for more days, although the difference
achieved statistical significance only for “high dose” metha-
done compared with LAAM. Most of the difference
between “high dose” methadone and LAAM occurred in
the first two weeks of treatment.
Implications for clinical practice
As most doses are supervised by a pharmacist, the possibil-
ity of less than daily dosing is a practical benefit of LAAM
and buprenorphine. This trial shows that thrice-weekly
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dosing with these medications reduces illicit opioid use to a
similar extent to that achieved with standard methadone
maintenance treatment, and indicates that both buprenor-
phine and LAAM are more effective than “low dose”
methadone. The lower retention rates associated with
LAAM make it necessary to have available an alternative
therapy for people who do not respond, and to give particu-
lar attention to patients during induction. More participants
in the LAAM group were withdrawn because of side effects,
but the details of these side effects were not reported, and
this needs to be explored further. This report did not
describe changes in participants’ health and social function-
ing, which are important in considering the overall effective-
ness of treatments for opioid dependence.
Buprenorphine is available in Australia, but LAAM is
available only under clinical trial arrangements.
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